Conversely, Niv+Ipi was, in terms of the efficacy of PFS and OS, inferior to Pem+PBC, which is currently recommended as the first-line treatment for PD-L1-positive advanced NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.